Q&A: Increased awareness may boost uptake of inhaled insulin

A form of inhaled insulin has been available for adults with type 1 and type 2 diabetes for nearly a decade, but providers say many people are not aware that it may be a treatment option for them.
In June 2014, the FDA approved a rapid-acting inhaled insulin (Afrezza, MannKind Pharma) for adults with type 1 and type 2 diabetes. The following year, two studies were published that found inhaled insulin was a therapeutic option for adults with diabetes. In the Affinity 1 trial, adults with type 1 diabetes had a noninferior reduction in HbA1c and fewer hypoglycemic events with inhaled insulin

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart